Diabetes Case Reports

Abstract

Shall We Consider DPP-4-Inhibitors as Cardiovascular Safe Drugs?

Jose Mario F de Oliveira

Cardiovascular diseases are by far the most frequent and deadly complications of type 2 diabetes mellitus. All recent anti-diabetic drugs have been shadowed by signals of more or less severe toxic side-effects, but the DPP-4 Inhibitors (DPP-4) have been gaining the reputation, based on interpretations of short and medium-term randomized clinical trials (RCT), and to pre-marketing rules of regulatory agencies, of being as a whole safe anti-diabetic drugs for type 2 diabetics.